Literature DB >> 9422543

Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease.

S Müller1, J Lory, N Corazza, G M Griffiths, K Z'graggen, L Mazzucchelli, A Kappeler, C Mueller.   

Abstract

The contribution of cell-mediated cytotoxicity to the pathogenesis of inflammatory bowel disease (IBD) is controversial, and results of in vitro assays vary according to experimental procedures. Therefore, we compared the frequency of cytotoxic effector cells in situ. On tissue sections of controls (n = 11), low frequencies of granzyme A and perforin mRNA-expressing cells are found in the lamina propria (1.77 +/- 0.15% and 1.46 +/- 0.12%, respectively) and in the epithelial cell layer (0.76 +/- 0.12% and 0.66 +/- 0.10%, respectively). In patients with IBD (n = 33), corresponding values were significantly (P < 0.02) higher, 6.1 +/- 0.40% and 5.92 +/- 0.57% for granzyme A and perforin expression in the lamina propria and 2.50 +/- 0.19% and 2.59 +/- 0.28%, respectively, in the epithelial compartment. Differences between ulcerative colitis and Crohn's disease are statistically not significant (P > 0.33). Activated cytotoxic cells are preferentially found at sites facing the intestinal lumen. Perforin mRNA-expressing cells are mainly CD8+ T cells. CD4+ T cells expressing perforin mRNA are mainly isolated from affected areas of patients with Crohn's disease. Immunostaining for perforin protein generally coincides with perforin mRNA in situ. These data demonstrate that cytotoxic cells are vigorously activated in situ in the intestinal mucosa of patients with active IBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422543      PMCID: PMC1858122     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

Review 1.  Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells.

Authors:  G M Griffiths; C Mueller
Journal:  Immunol Today       Date:  1991-11

2.  The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease.

Authors:  K Z'Graggen; A Walz; L Mazzucchelli; R M Strieter; C Mueller
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

3.  Structure and function of human perforin.

Authors:  M G Lichtenheld; K J Olsen; P Lu; D M Lowrey; A Hameed; H Hengartner; E R Podack
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

4.  Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect.

Authors:  C H Ginsburg; J T Dambrauskas; K A Ault; Z M Falchuk
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

5.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.

Authors:  B Sadlack; H Merz; H Schorle; A Schimpl; A C Feller; I Horak
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

6.  Major histocompatibility antigen-restricted cytotoxicity in inflammatory bowel disease.

Authors:  K Okazaki; M Morita; I Nishimori; S Sano; M Toyonaga; Y Nakazawa; Y Yamamoto; Y Yamamoto
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

7.  Anti-CD2 and anti-CD3 induced T cell cytotoxicity of human intraepithelial and lamina propria lymphocytes.

Authors:  J Rüthlein; G Heinze; I O Auer
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

8.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity.

Authors:  E Rouvier; M F Luciani; P Golstein
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

9.  A high proportion of T lymphocytes that infiltrate H-2-incompatible heart allografts in vivo express genes encoding cytotoxic cell-specific serine proteases, but do not express the MEL-14-defined lymph node homing receptor.

Authors:  C Mueller; H K Gershenfeld; C G Lobe; C Y Okada; R C Bleackley; I L Weissman
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8.

Authors:  A Walz; R Burgener; B Car; M Baggiolini; S L Kunkel; R M Strieter
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  33 in total

1.  Mesenchymal Stromal Cells Mitigate Experimental Colitis via Insulin-like Growth Factor Binding Protein 7-mediated Immunosuppression.

Authors:  Yan Liao; Junxia Lei; Muyun Liu; Wanwen Lin; Dongxi Hong; Ying Tuo; Mei Hua Jiang; Huimin Xia; Maosheng Wang; Weijun Huang; Andy Peng Xiang
Journal:  Mol Ther       Date:  2016-07-09       Impact factor: 11.454

2.  Appendix is a priming site in the development of ulcerative colitis.

Authors:  Mitsunobu Matsushita; Hiroshi Takakuwa; Yuji Matsubayashi; Akiyoshi Nishio; Susumu Ikehara; Kazuichi Okazaki
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

Review 3.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

4.  HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis.

Authors:  T Sunagawa; Y Yonamine; F Kinjo; M Watanabe; T Hibi; A Saito
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

5.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 6.  Intestinal inflammation and colorectal cancer: a double-edged sword?

Authors:  Angelamaria Rizzo; Francesco Pallone; Giovanni Monteleone; Massimo Claudio Fantini
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

7.  Therapeutic efficacy of a mutant of keratinocyte growth factor-2 on trinitrobenzene sulfonic acid-induced rat model of Crohn's disease.

Authors:  Jinfeng Wang; Huihua Chen; Yuanyuan Wang; Xin Cai; Minji Zou; Tao Xu; Min Wang; Jiaxi Wang; Donggang Xu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

8.  Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

Authors:  B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 9.  Colitis-associated cancer: the role of T cells in tumor development.

Authors:  Maximilian J Waldner; Markus F Neurath
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

10.  Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.

Authors:  G Bisping; N Lügering; S Lütke-Brintrup; H G Pauels; G Schürmann; W Domschke; T Kucharzik
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.